Skip to main content

Tesamorelin vs Semax

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Full details →

Semax

Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone). Developed in Russia as a nootropic and neuroprotective agent.

Full details →

Side-by-Side Comparison

AspectTesamorelinSemax
MechanismStimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue.Enhances BDNF expression, modulates dopamine and serotonin systems, and provides neuroprotective effects. Increases attention, memory formation, and learning.
Typical DosageFDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules.Intranasal: 200-600mcg 2-3 times daily. Higher doses (up to 1mg) used in clinical settings for stroke recovery.
AdministrationSubcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening.Primarily administered intranasally. N-Acetyl Semax Amidate (NASA) is a modified version with enhanced stability and potency.
Side EffectsCommon side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose.Generally well-tolerated. May cause mild irritability or hair shedding in some users.
Best For

Key Differences

Unique to Tesamorelin:

Unique to Semax:

Detailed Analysis

Semax and Tesamorelin are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Semax for Cognitive Performance. Choose Tesamorelin for Muscle Growth, Fat Loss.

Ready to Learn More?